DE69130569D1 - Mit psoralen konjugierte methylphosphonat-oligonukleotide als therapeutische wirkstoffe für chronische myologene leukämie - Google Patents
Mit psoralen konjugierte methylphosphonat-oligonukleotide als therapeutische wirkstoffe für chronische myologene leukämieInfo
- Publication number
- DE69130569D1 DE69130569D1 DE69130569T DE69130569T DE69130569D1 DE 69130569 D1 DE69130569 D1 DE 69130569D1 DE 69130569 T DE69130569 T DE 69130569T DE 69130569 T DE69130569 T DE 69130569T DE 69130569 D1 DE69130569 D1 DE 69130569D1
- Authority
- DE
- Germany
- Prior art keywords
- psoral
- myological
- conjuguged
- oligonucleotid
- methylphosphonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3511—Conjugate intercalating or cleaving agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3527—Other alkyl chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56529990A | 1990-08-09 | 1990-08-09 | |
PCT/US1991/005690 WO1992002641A1 (en) | 1990-08-09 | 1991-08-09 | Psoralen conjugated methylphosphonate oligonucleotides as therapeutic agents for chronic myelogenous leukemia |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69130569D1 true DE69130569D1 (de) | 1999-01-14 |
DE69130569T2 DE69130569T2 (de) | 1999-05-27 |
Family
ID=24258000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69130569T Expired - Fee Related DE69130569T2 (de) | 1990-08-09 | 1991-08-09 | Mit psoralen konjugierte methylphosphonat-oligonukleotide als therapeutische wirkstoffe für chronische myologene leukämie |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0542887B1 (de) |
JP (1) | JPH06500322A (de) |
KR (1) | KR930701627A (de) |
AT (1) | ATE174063T1 (de) |
AU (2) | AU8400391A (de) |
CA (1) | CA2089088A1 (de) |
DE (1) | DE69130569T2 (de) |
IE (1) | IE912806A1 (de) |
IL (1) | IL99069A (de) |
NZ (1) | NZ239252A (de) |
WO (1) | WO1992002641A1 (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992022303A1 (en) * | 1991-06-18 | 1992-12-23 | Temple University - Of The Commonwealth System Of Higher Education | Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides |
GB9123947D0 (en) * | 1991-11-12 | 1992-01-02 | Imp Cancer Res Tech | Therapeutic compounds |
FR2703053B1 (fr) * | 1993-03-26 | 1995-06-16 | Genset Sa | Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications . |
US5556993A (en) | 1993-06-28 | 1996-09-17 | Steritech, Inc. | Compounds for the photodecontamination of pathogens in blood |
US6420570B1 (en) | 1993-06-28 | 2002-07-16 | Cerus Corporation | Psoralen compounds |
US5399719A (en) | 1993-06-28 | 1995-03-21 | Steritech, Inc. | Compounds for the photodecontamination of pathogens in blood |
JP2003525848A (ja) | 1997-11-20 | 2003-09-02 | セラス コーポレーション | 病原体を不活化するための新規なソラレン |
SI2056845T1 (en) | 2006-08-08 | 2018-02-28 | Rheinische Friedrich-Wilhelms-Universitaet Bonn | STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES |
EP2297323A1 (de) | 2008-05-21 | 2011-03-23 | Hartmann, Gunther | 5 -triphosphat-oligonukleotid mit stumpfem ende und verwendugen davon |
EP2508530A1 (de) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags |
EP2712870A1 (de) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Neuartige RIG-I-Liganden und Herstellungsverfahren dafür |
EP4371992A1 (de) * | 2022-11-17 | 2024-05-22 | YongNong BioSciences Co., Ltd | Verfahren zur herstellung von glufosinat |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3012244B2 (ja) * | 1987-09-21 | 2000-02-21 | ジェン―プローブ インコーポレイテッド | ヌクレオチドプローブ用非ヌクレオチド連結試薬 |
PT88665B (pt) * | 1987-10-05 | 1992-12-31 | Ml Tecnology Ventures Lp | Metodo para a marcacao com ester de acridinio e purificacao de sondas nucleotidicas |
US4999290A (en) * | 1988-03-31 | 1991-03-12 | The Board Of Regents, The University Of Texas System | Detection of genomic abnormalities with unique aberrant gene transcripts |
NZ239250A (en) * | 1990-08-09 | 1993-12-23 | Genta Inc | Chirally pure non-nucleotide reagents for use in preparing |
-
1991
- 1991-08-02 IL IL9906991A patent/IL99069A/en active IP Right Grant
- 1991-08-02 NZ NZ239252A patent/NZ239252A/en unknown
- 1991-08-08 IE IE280691A patent/IE912806A1/en unknown
- 1991-08-09 JP JP3514157A patent/JPH06500322A/ja active Pending
- 1991-08-09 AU AU84003/91A patent/AU8400391A/en not_active Abandoned
- 1991-08-09 CA CA002089088A patent/CA2089088A1/en not_active Abandoned
- 1991-08-09 DE DE69130569T patent/DE69130569T2/de not_active Expired - Fee Related
- 1991-08-09 WO PCT/US1991/005690 patent/WO1992002641A1/en active IP Right Grant
- 1991-08-09 AT AT91915657T patent/ATE174063T1/de not_active IP Right Cessation
- 1991-08-09 EP EP91915657A patent/EP0542887B1/de not_active Expired - Lifetime
-
1993
- 1993-02-09 KR KR1019930700370A patent/KR930701627A/ko not_active Application Discontinuation
-
1996
- 1996-06-25 AU AU56180/96A patent/AU693690B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
EP0542887A4 (en) | 1993-09-08 |
DE69130569T2 (de) | 1999-05-27 |
CA2089088A1 (en) | 1992-02-10 |
AU693690B2 (en) | 1998-07-02 |
NZ239252A (en) | 1997-07-27 |
JPH06500322A (ja) | 1994-01-13 |
EP0542887A1 (de) | 1993-05-26 |
KR930701627A (ko) | 1993-06-12 |
EP0542887B1 (de) | 1998-12-02 |
ATE174063T1 (de) | 1998-12-15 |
WO1992002641A1 (en) | 1992-02-20 |
IE912806A1 (en) | 1992-02-12 |
AU5618096A (en) | 1996-10-10 |
IL99069A (en) | 1998-08-16 |
AU8400391A (en) | 1992-03-02 |
IL99069A0 (en) | 1992-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69130569D1 (de) | Mit psoralen konjugierte methylphosphonat-oligonukleotide als therapeutische wirkstoffe für chronische myologene leukämie | |
FI905327A0 (fi) | Foerfarande foer blekning av massa utan klor. | |
IT8919974A0 (it) | Emulsioni stabili di perfluoropolieteri. | |
PT653439E (pt) | Oligonucleotidos e sua aplicacao | |
ATE529509T1 (de) | Selektion von proteinen unter verwendung von rna- protein-fusionen | |
DE69110854D1 (de) | Antivirusderivate von (Phosphonmethoxy)Methoxy Purin/Pyrimidin. | |
FI893428A (fi) | Eliminering av toxiska egenskaper in vitro och in vivo hos tnf-a medelst monoklonala antikroppar och fragment haerledda fraon dessa. | |
DK0754229T3 (da) | Afamin: et humant serum albumin-lignende protein | |
FI913391A0 (fi) | Foerfarande foer detektering av smaocellcarcinom och anvaendning av acylpeptidhydrolas och denna kodande sekvenser. | |
DE69106562D1 (de) | Oberfläche mit verringerter Proteinwechselwirkung. | |
BR0009170A (pt) | ácidos nucléicos akt, polipeptìdeos e uso dos mesmos | |
IT8722641A0 (it) | Piedino abbattibile per mobili. | |
DE69831229D1 (de) | Schnelle bestimmung des verhältnisses von biologischen molekülen | |
DE58907786D1 (de) | Optische Messanordnung zum Nachweis von Kavitationsblasen in Flüssigkeiten. | |
AU7423391A (en) | Dna constructs for the expression of proteins in the mammary gland of transgenetic mammals | |
DE69009752D1 (de) | Differentieller verstärker mit gewinnausgleich. | |
DE69837935D1 (de) | Nukleotid- und proteinsequenz von mammastatin und anwendungsmethoden | |
DE69433352D1 (de) | Überexpression von einzelsträngigen dna molekülen | |
DK614489D0 (da) | Peptidderivater | |
DE68912536D1 (de) | Flüssiges Nahrungsmittel zur Proteinzuführung. | |
IT8905141A0 (it) | Misuratore ottico adatto per determinare la percentuale di proteine contenute nel latte. | |
DE59009060D1 (de) | Überexpression von Proteinen in rekombinanten Wirtszellen. | |
DK37990A (da) | Dna-probe | |
ATE184767T1 (de) | Untermatratze | |
PT83519A (de) | Promotor-anordnung fuer streptomyceten-vektoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |